Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHWSL.L Regulatory News (HWSL)

  • There is currently no data for HWSL

Net Asset Value(s)

4 May 2020 09:24

RNS Number : 8033L
HWSI Realisation Fund Ltd
04 May 2020
 

 

HWSI Realisation Fund Limited

(the "Company")

Net Asset Value and Investment Update

 

NAV

The Company announces that the unaudited cum-income net asset value per Ordinary Share as at 31 March 2020 was 61.20 pence, after deducting the 19 pence per share capital distribution by way of B share issue and redemption that was announced on 31 March. The Ordinary Shares went ex the entitlement on 6 April. Prior to deducting the capital distribution the net asset value per Ordinary Share cum income would have been 80.20 pence.

Investment Update

Shareholders will recall that in the Company's announcement dated 27 March 2020, the Board, the Investment Manager and Hadrian's Wall Capital (the "Investment Adviser") acknowledged that Covid-19 was likely to have a detrimental effect on portfolio investments. The spread of Covid-19 and the associated impact on economic activity has led to significant volatility in both the equity and debt capital markets, as well as to other market indicators such as interest rates and forecast inflation. Whilst the net asset value as at 29 February 2020 was published at a much earlier stage of the pandemic, the situation remains fluid and it is the Investment Adviser's and the Board's view that it is not possible to estimate with any certainty the impact of Covid-19 on the portfolio at this time. Nevertheless, there have been a number of specific developments in the portfolio and a number of requests for forbearance have been received from the Company's borrowers.

Forbearance requests are being dealt with on a case-by-case basis. In each case the Investment Adviser is working closely with borrowers to:

1. Help them survive this pandemic and continue to be economically viable; and

 

2. Ensure that any forbearance tries to protect the full economic interest of the Company (both interest and capital protection)

 

At the date of this announcement, 10 Loans (representing a cumulative total of £71.1m of principal outstanding loan balances) have requested forbearance of some kind. The request for forbearance arrangements include, but not limited to:

· three months' deferred interest and capital payments,

· a proportional payment of interest due based on their actual collections as a percentage of expected collections,

· full interest on the deployed capital and a reduced rate of interest to be charged on the variable cash at bank in the borrower SPV.

 

All forbearance requests and agreements are being reviewed on a monthly basis or as extraordinary circumstances arise.

 

As a prudent measure, with very few exceptions, loans in the portfolio have had an increase in expected losses arising from a movement in the relevant risk category solely by virtue of the fact that Covid-19 will have to a greater or lesser extent, an impact on the Company's Loans and this has to be recognised. Eight borrowers have had their risk ratings downgraded or their Expected Loss adjusted to the full level of the Risk Category. In total the Expected Credit Loss provision has increased by £2.7m (equivalent to 1.9p per share) during the month bringing the aggregate Expected Loss provisions to £28.4m.

 

As new facts and information come to light as to the impact of Covid-19 on the Loans, the Board will review the need for any additional provisioning and will keep shareholders updated on material developments.

The Board, after due consideration and following recommendations from the Investment Adviser, has determined that the above changes to the IFRS9 provisions to reflect the developments in the portfolio, caused by the uncertainties associated with the COVID-19 pandemic, are prudent.

Other portfolio developments

The Company announced on 27 June 2019 that one of the Company's borrowers was in the process of undertaking an equity raise or company sale. Whilst this process has been progressing, it was originally hoped that it would conclude in the first quarter of 2020 so as to ensure full repayment of the loan at its face value of £13 million, plus accrued interest. Whilst the Investment Adviser still believes it more likely than not that the equity raise or company sale will conclude, the timeframe for conclusion has become more uncertain owing in part to Covid19. The IFRS 9 general loss reserve has not been adjusted on this loan, including as a result of any Covid-19 impact (it being currently £2 million plus accrued interest). Whilst the indicated valuations of the portfolio company support a full recovery, the borrower has limited liquidity and consequently a further delay could expose the Company to the risk of material loss. In the circumstances, it is possible that the borrower might request the Company to provide additional capital for working capital purposes. The Board continues to monitor this situation closely given the significance of this loan in the overall position of the Company's loan portfolio.

Contact Details:

 

Hadrian's Wall Capital (Investment Adviser)

Ron Miao / Mike Schozer

Telephone 020 3026 8620

 

International Fund Management (Investment Manager)

Chris Hickling

Telephone: 01481 737600

 

Praxis Fund Services Limited (Administrator)

Ben Le Prevost

Telephone: 01481 755524

 

Winterflood Investment Trusts (Corporate Broker)

Neil Morgan

Telephone: 020 3100 0000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NAVUPUUPAUPUURC
Date   Source Headline
27th May 20207:00 amRNSNet Asset Value(s)
11th May 202011:38 amRNSHolding(s) in Company
5th May 20204:15 pmRNSPortfolio Update
4th May 20209:24 amRNSNet Asset Value(s)
1st May 20205:49 pmRNSHolding(s) in Company
30th Apr 202012:01 pmRNSHolding(s) in Company
27th Apr 20206:25 pmRNSArticles of Incorporation re LR 9.2.6ER(1)
6th Apr 20204:43 pmRNSSecond Price Monitoring Extn
6th Apr 20204:37 pmRNSPrice Monitoring Extension
2nd Apr 20209:00 amRNSDirector/PDMR Shareholding
27th Mar 202011:08 amRNSNet Asset Value(s)
23rd Mar 20204:07 pmRNSPortfolio Update
20th Mar 20201:12 pmRNSResult of EGM and Change of Name
17th Mar 20203:33 pmRNSHolding(s) in Company
5th Mar 20209:08 amRNSPublication of Circular and Notice of EGM
28th Feb 20207:00 amRNSNet Asset Value(s)
19th Feb 20203:30 pmRNSTermination of Investment Advisory Agreement
13th Feb 20208:25 amRNSHolding(s) in Company
11th Feb 20201:57 pmRNSCompany Update - Replacement
11th Feb 202012:08 pmRNSSecond Price Monitoring Extn
11th Feb 202012:03 pmRNSPrice Monitoring Extension
10th Feb 202012:40 pmRNSPortfolio Update
10th Feb 202012:35 pmRNSCompany Update
10th Feb 202012:30 pmRNSNet Asset Value(s)
7th Feb 20204:01 pmRNSDividend Declaration
5th Feb 20205:10 pmRNSHolding(s) in Company
5th Feb 202010:18 amRNSHolding(s) in Company
31st Jan 20205:01 pmRNSHolding(s) in Company
31st Jan 202012:19 pmRNSHolding(s) in Company
30th Jan 202011:26 amRNSHolding(s) in Company
2nd Jan 20207:00 amRNSNet Asset Value(s)
17th Dec 20195:02 pmRNSNet Asset Value and Company Update
9th Dec 20194:44 pmRNSDirectorate Changes
9th Dec 20194:41 pmRNSResult of AGM
9th Dec 20198:00 amRNSCompany Update
20th Nov 20196:13 pmRNSHolding(s) in Company
20th Nov 20197:00 amRNSPortfolio Update
8th Nov 201910:53 amRNSHolding(s) in Company
31st Oct 201912:28 pmRNSHolding(s) in Company
29th Oct 201911:32 amRNSHolding(s) in Company
25th Oct 201910:00 amRNSPortfolio Update
25th Oct 20199:45 amRNSNet Asset Value(s)
25th Oct 20197:00 amRNSAnnual Financial Report and Notice of AGM
24th Oct 20196:05 pmRNSHolding(s) in Company
24th Oct 20195:30 pmRNSDividend Declaration
4th Oct 201912:20 pmRNSNet Asset Value(s)
2nd Oct 20197:00 amRNSPortfolio Update
1st Oct 20198:00 amRNSTotal Voting Rights
10th Sep 201911:26 amRNSHolding(s) in Company
10th Sep 201911:14 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.